ArticleAME case reports2025
Radical tumor resection of a relapsed high-grade endometrial stromal sarcoma with an extremely rare mutation: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial stromal sarcomas (ESS) are rare uterine mesenchymal tumors that histologically resemble endometrial stroma of functioning endometrium. The key characteristic of those tumors is the difficulty to diagnose preoperatively that leads to high rate of misdiagnosis. The aim of this case report is to present an extremely rare mutation of these already rare tumors and urge for more personalized therapies in the future. Case Description: We present a case of a 62-year-old postmenopausal patient initially diagnosed with high-grade ESS (HG-ESS). In her routine follow-up, her computerized tomography (CT) and positron emission tomography-CT (PET-CT) scan showed a relapse in the vaginal vault and enlarged left iliac lymph nodes. The patient did not respond to chemotherapy and suffered from severe abdominal pain and her quality of life severely deteriorated. A cytoreduction laparotomic surgery was decided with complete resection (R0) of the tumor in the pelvis with no visible residual disease. Chemosensitivity and gene expression analysis report showed a high tumor mutation burden with 11 mutations/Mb and the detection of Conclusions: Recurrent or advanced tumors should be treated aggressively with chemotherapy and radiation. Effort for complete resection and targeted therapy should be offered to the patients. Discovery of rare mutations might offer better personalized therapies in the future. Despite its radicality, cytoreductive surgery is a valid option in cases where life quality has severely deteriorated, offering a few qualitative months of life to the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.